Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04702737
Recruitment Status : Recruiting
First Posted : January 11, 2021
Last Update Posted : April 29, 2022
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 28, 2023
Estimated Study Completion Date : January 4, 2026